Glaxo Mimics Carmaker to Speed Vaccine

Using the "one roof" management technique developed by Renault, the British pharma rushed its HPV vaccine to close the gap with rival Merck

It's potentially the most lucrative vaccine ever developed: An innovative inoculation that protects against the human papilloma virus (HPV), the main cause of cervical cancer—the second deadliest female cancer worldwide. And for Britain's GlaxoSmithKline (GSK), which on Mar. 29 submitted its Cervarix vaccine to the U.S. Food and Drug Administration for approval, it's also a major driver of future success, perhaps contributing up to one-third of sales and profit growth over the next five years.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.